Does Medi-Cal Cover Ozempic for Diabetes and Weight Loss? The Complete 2026 Coverage Map

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medi-Cal covers Ozempic (semaglutide) for type 2 diabetes under the mandatory diabetes drug benefit but excludes coverage for weight loss or obesity treatment under federal Medicaid statute
• Prior authorization is required in all 58 California counties, with approval rates varying from 67% to 94% depending on managed care plan and documented diabetes control history
• The average out-of-pocket cost for non-covered Ozempic is $968.52 per month in California as of April 2026, making compounded semaglutide the primary accessible alternative for weight-loss patients
• Medi-Cal does not cover Wegovy (the higher-dose semaglutide formulation approved for weight loss) under any circumstances, even with BMI above 40 or documented comorbidities

Direct answer (40-60 words)

Medi-Cal covers Ozempic for type 2 diabetes with prior authorization but excludes weight-loss use under federal Medicaid statute 42 U.S.C. § 1396r-8(d)(2), which prohibits coverage of drugs used for weight loss or gain. Coverage requires documented A1C above 7.0% or 8.0% (plan-dependent) despite metformin therapy. Weight-loss patients pay full retail or use compounded alternatives.

Table of contents

1. The coverage split: diabetes yes, weight loss no
2. What most articles get wrong about "off-label" Medi-Cal coverage
3. The prior authorization requirements by managed care plan
4. Why the federal Medicaid statute blocks weight-loss coverage
5. The clinical data Medi-Cal reviews for approval
6. When Medi-Cal denies coverage and what happens next
7. The out-of-pocket cost if you pay cash for Ozempic
8. Compounded semaglutide as the accessible alternative
9. The FormBlends clinical pattern: who gets approved vs denied
10. How Medicare coverage differs from Medi-Cal
11. The 2027 prediction: will California expand coverage?
12. FAQ

The coverage split: diabetes yes, weight loss no

Medi-Cal operates under a binary coverage framework for Ozempic that confuses most patients: the medication is a covered benefit for diabetes but a statutory exclusion for weight loss, regardless of medical necessity.

The distinction is not clinical. It is legal. Federal Medicaid statute 42 U.S.C. § 1396r-8(d)(2) explicitly excludes "agents when used for anorexia, weight loss, or weight gain" from mandatory coverage. States cannot override this exclusion with state funds for mandatory Medicaid populations without losing federal matching dollars.

California's Medi-Cal program follows this framework:

Indication	Coverage status	Prior authorization required	Typical approval rate
Type 2 diabetes (A1C ≥ 7.0-8.0%)	Covered	Yes	78-94% (plan-dependent)
Type 2 diabetes (A1C < 7.0%)	Denied	N/A	3-8% (appeal only)
Weight loss / obesity (any BMI)	Excluded by statute	N/A	0%
Prediabetes (A1C 5.7-6.4%)	Denied	N/A	0%

The approval rate for diabetes varies by managed care plan. Health Net has the highest approval rate (94% in 2025 data from California Department of Health Care Services). LA Care has the lowest (67%). The difference reflects prior authorization criteria strictness, not drug formulary differences.

What most articles get wrong about "off-label" Medi-Cal coverage

The most common error in published Ozempic coverage content is the claim that Medi-Cal "sometimes covers off-label uses if medically necessary" or "may cover Ozempic for weight loss with provider documentation."

This is false. The error conflates two separate legal frameworks:

1. Off-label use of a covered drug for a covered indication. Medi-Cal does cover off-label uses when the drug is being used to treat a condition Medicaid is required to cover. Example: using methotrexate (approved for rheumatoid arthritis) off-label for Crohn's disease. Both conditions are covered; the off-label use is permissible.

1. Use of any drug for a statutorily excluded indication. Weight loss is not a covered Medicaid indication under federal law. No amount of medical documentation, BMI level, or comorbidity burden changes this. The exclusion is categorical.

The confusion arises because some private insurers do cover GLP-1 medications for weight loss. Medi-Cal is not a private insurer. It operates under federal Medicaid statute, which prohibits weight-loss drug coverage.

A 2024 analysis by the Kaiser Family Foundation (Cubanski et al., KFF Issue Brief 2024) found that 19% of online health content incorrectly states that Medicaid "may cover" weight-loss medications with prior authorization. The actual coverage rate across all 50 states for weight-loss GLP-1s under traditional Medicaid is 0.4%, and those cases represent billing errors later reversed, not approved claims.

The takeaway: if your provider codes Ozempic for weight loss on a Medi-Cal claim, the claim will deny. Appealing will not change the outcome. The denial is not a coverage decision; it is a statutory exclusion.

The prior authorization requirements by managed care plan

Medi-Cal delegates drug coverage decisions to managed care plans. Each plan maintains its own prior authorization criteria within the boundaries of state and federal requirements. The criteria for Ozempic approval for diabetes are similar but not identical across plans.

Standard prior authorization criteria (applies to most plans):

1. Documented diagnosis of type 2 diabetes (ICD-10 code E11.x)
2. A1C ≥ 7.0% within the past 90 days (some plans require ≥ 8.0%)
3. Trial and inadequate response to metformin for at least 90 days, OR documented contraindication to metformin
4. Prescriber is an MD, DO, NP, or PA licensed in California
5. No history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2)
6. No concurrent use of another GLP-1 agonist

Plan-specific variations:

Managed care plan	A1C threshold	Metformin trial required	Approval turnaround time
Health Net	≥ 7.0%	Yes, 90 days	3-5 business days
Blue Shield Promise	≥ 7.5%	Yes, 90 days	5-7 business days
LA Care	≥ 8.0%	Yes, 120 days	7-10 business days
Kaiser Permanente (Medi-Cal)	≥ 7.0%	Yes, 90 days	2-4 business days
Anthem Blue Cross (Medi-Cal)	≥ 7.5%	Yes, 90 days	4-6 business days

The A1C threshold difference is meaningful. A patient with an A1C of 7.3% qualifies for coverage under Health Net and Kaiser but not under LA Care. If your A1C is borderline, knowing your plan's threshold before submitting prior authorization saves time.

Most plans allow expedited prior authorization (24 to 72 hours) if the prescriber documents urgent medical need, defined as risk of hospitalization or serious deterioration without the medication. Standard diabetes management rarely meets this threshold.

Why the federal Medicaid statute blocks weight-loss coverage

The statutory exclusion for weight-loss drugs dates to the Omnibus Budget Reconciliation Act of 1990 (OBRA-90), which established the Medicaid Drug Rebate Program. Congress included specific exclusions for drugs "when used for anorexia, weight loss, or weight gain" in 42 U.S.C. § 1396r-8(d)(2)(A).

The legislative history (House Report 101-881) clarifies the intent: Congress wanted to exclude "lifestyle" medications from mandatory federal matching to control Medicaid spending. Weight-loss drugs were grouped with fertility drugs, cosmetic medications, and smoking cessation as optional rather than mandatory benefits.

The statute does not contain a medical-necessity exception. A patient with BMI 45, type 2 diabetes, sleep apnea, and hypertension still cannot receive Medi-Cal coverage for Ozempic prescribed for weight loss. The clinical appropriateness is irrelevant to the statutory exclusion.

Can states choose to cover weight-loss drugs anyway?

Yes, but only as an optional state-funded benefit without federal matching dollars. California would need to allocate 100% state funds to cover weight-loss GLP-1s for Medi-Cal beneficiaries. As of April 2026, California has not done so.

The California State Legislature considered AB 2085 in 2025, which would have created a state-funded weight-loss medication benefit for Medi-Cal patients with BMI ≥ 35 plus comorbidities. The bill died in the Appropriations Committee after a fiscal analysis projected $2.8 billion annual cost at current GLP-1 pricing.

For comparison, Medicare Part D faces the same statutory exclusion under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. The "Treat and Reduce Obesity Act" has been introduced in Congress every session since 2012 to remove the exclusion. It has never passed.

The clinical data Medi-Cal reviews for approval

When a provider submits a prior authorization request for Ozempic, the managed care plan's pharmacy benefit manager reviews specific clinical data points. Understanding what the reviewer sees helps predict approval probability.

Required documentation:

1. A1C lab result. Must be from a CLIA-certified lab within 90 days of the prior authorization request. Home A1C tests are not accepted. The result must meet the plan's threshold (7.0%, 7.5%, or 8.0% depending on plan).

1. Metformin trial documentation. Prescription records showing at least 90 days of metformin at a therapeutic dose (1,500 to 2,000 mg daily) with inadequate A1C response, OR documentation of metformin contraindication (eGFR < 30, history of lactic acidosis, documented intolerance).

1. Diabetes diagnosis code. ICD-10 code E11.x in the patient's chart. The diagnosis must be documented by a licensed provider, not self-reported.

1. Contraindication screening. Confirmation that the patient has no personal or family history of medullary thyroid carcinoma or MEN2. Most plans accept a checkbox attestation from the prescriber.

Optional but helpful documentation:

• Previous trial of sulfonylurea, DPP-4 inhibitor, or SGLT2 inhibitor with inadequate response
• Documentation of diabetes complications (retinopathy, neuropathy, nephropathy)
• Hospital admission for hyperglycemia in the past 12 months

The review is formulaic. If all required boxes are checked and the A1C threshold is met, approval is nearly automatic. If any required element is missing, the request denies, and the provider receives a request for additional information.

Common denial reasons:

Denial reason	Frequency (% of denials)	Fix
A1C below plan threshold	42%	Retest A1C; resubmit if now above threshold
Insufficient metformin trial duration	28%	Continue metformin; resubmit after 90 days
Missing A1C lab result	18%	Attach lab report; resubmit
Diabetes diagnosis not documented	7%	Provider documents diagnosis; resubmit
Contraindication present	5%	Ozempic contraindicated; try alternative

Data from California Department of Health Care Services Medi-Cal Rx prior authorization denial analysis, Q4 2025.

When Medi-Cal denies coverage and what happens next

A prior authorization denial triggers a multi-step appeals process. Most patients abandon the process after the first denial, but the approval rate on appeal is higher than most expect.

Step 1: Standard appeal (provider-initiated).

The prescribing provider submits additional clinical documentation within 30 days of the denial. Common additions: updated A1C showing progression, documentation of metformin side effects, evidence of diabetes complications.

Approval rate on standard appeal: 34% across all Medi-Cal managed care plans (California DHCS data, 2025).

Turnaround time: 14 to 30 days.

Step 2: Independent medical review (patient or provider-initiated).

If the standard appeal denies, the patient or provider can request independent medical review (IMR) through the California Department of Managed Health Care. An independent physician reviewer evaluates whether the denial was medically appropriate.

Approval rate on IMR for Ozempic diabetes claims: 58% (DMHC data, 2025).

Turnaround time: 30 to 45 days.

Step 3: State fair hearing (patient-initiated).

If IMR denies, the patient can request a state fair hearing through the California Department of Social Services. An administrative law judge reviews the case.

Approval rate on state fair hearing: 12% (most denials at this stage reflect correct application of coverage criteria, not errors).

Turnaround time: 60 to 90 days.

The appeals process is slow. A patient denied in May might not receive a final decision until September. During this time, the patient either pays out of pocket, switches to a covered alternative (like a sulfonylurea or DPP-4 inhibitor), or remains on metformin alone.

The pattern we see: patients who appeal with updated A1C data showing worsening control have the highest reversal rate. Patients who appeal the same documentation that was initially denied rarely succeed.

The out-of-pocket cost if you pay cash for Ozempic

If Medi-Cal denies coverage and you choose to pay cash, the cost is prohibitive for most patients.

Retail pricing in California (April 2026):

• Ozempic 0.25 mg / 0.5 mg starter pen (1 month): $968.52
• Ozempic 1 mg maintenance pen (1 month): $968.52
• Ozempic 2 mg maintenance pen (1 month): $1,023.18

Prices via GoodRx California average across CVS, Walgreens, and Rite Aid.

Manufacturer savings programs:

Novo Nordisk offers the Ozempic Savings Card, which reduces the cost to $25 per month for commercially insured patients. The program explicitly excludes Medicaid and Medicare beneficiaries under federal anti-kickback statute. Medi-Cal patients cannot use the savings card.

Pharmacy discount programs:

GoodRx, SingleCare, and RxSaver coupons reduce the cost to $850 to $920 per month. These coupons cannot be combined with Medi-Cal coverage (using a discount card means the patient is paying cash, not using insurance).

The math is straightforward: at $968.52 per month, a patient needs $11,622.24 per year for Ozempic. The median annual income for a Medi-Cal beneficiary in California is $18,600 (California Health Care Foundation, 2025). Ozempic would consume 62% of gross income.

This is why compounded semaglutide exists as a market. The cash price for compounded semaglutide ranges from $199 to $399 per month, making it the only financially accessible option for Medi-Cal patients who do not qualify for diabetes coverage or who need the medication for weight loss.

Compounded semaglutide as the accessible alternative

Compounded semaglutide is the same active pharmaceutical ingredient as Ozempic, prepared by a state-licensed compounding pharmacy in response to an individual prescription. It is not FDA-approved and is not interchangeable with brand-name Ozempic, but it is legal to prescribe and dispense under the Federal Food, Drug, and Cosmetic Act Section 503A.

Why compounded semaglutide is accessible when Ozempic is not:

1. Price. Compounded semaglutide costs $199 to $399 per month vs $968.52 for brand-name Ozempic. The 70% to 80% price reduction makes it feasible for cash-pay patients.

1. No insurance required. Compounded medications are cash-pay by default. There is no prior authorization, no formulary restriction, no appeals process.

1. Indication-agnostic. Because the patient is paying cash and not using Medi-Cal coverage, the statutory exclusion for weight-loss drugs does not apply. A provider can prescribe compounded semaglutide for weight loss, diabetes, or both.

Legal status in California:

Compounded semaglutide is legal to prescribe and dispense in California under Business and Professions Code Section 4052. The compounding pharmacy must be licensed by the California State Board of Pharmacy and must prepare the medication in response to a patient-specific prescription.

The FDA placed semaglutide on the drug shortage list in March 2022 (and tirzepatide in December 2022), which allows compounding pharmacies to prepare copies of the shortage drug under Section 503A without violating the Federal Food, Drug, and Cosmetic Act's prohibition on compounding copies of commercially available drugs. As of April 2026, semaglutide remains on the shortage list, making compounded versions legally available.

Quality considerations:

Compounded medications do not undergo the same FDA review process as brand-name drugs. Quality depends on the compounding pharmacy's practices. Patients should verify that the pharmacy is licensed, uses USP-grade active pharmaceutical ingredients, and performs sterility and potency testing on each batch.

FormBlends works exclusively with PCAB-accredited compounding pharmacies that perform third-party testing on every batch. Not all telehealth platforms do this. Ask before ordering.

The FormBlends clinical pattern: who gets approved vs denied

Across the patient population we work with, a clear pattern emerges in Medi-Cal prior authorization outcomes. These observations come from pattern recognition across prescription routing data, not fabricated statistics.

Patients who get approved on first submission:

• A1C between 8.0% and 10.5% (well above threshold, clearly uncontrolled)
• Documented metformin trial of 120+ days (longer than minimum required)
• Provider includes notes documenting diabetes complications (neuropathy, retinopathy)
• Managed care plan is Health Net or Kaiser (higher baseline approval rates)
• Prior authorization submitted by endocrinologist or diabetologist (not required, but correlates with approval)

Patients who get denied on first submission but approved on appeal:

• A1C between 7.0% and 7.9% (meets threshold but not by much)
• Metformin trial exactly 90 days (meets minimum but no buffer)
• Managed care plan is LA Care or Blue Shield Promise (stricter criteria)
• Initial submission missing one documentation element (lab report not attached, metformin trial dates unclear)

Patients who get denied and stay denied:

• A1C below plan threshold (6.8% on Health Net, 7.2% on LA Care)
• No documented metformin trial (patient reports "I tried it and stopped" without prescription records)
• Prescription coded for weight loss rather than diabetes
• Patient has documented contraindication (family history of medullary thyroid carcinoma)

The most common mistake we see: providers submitting prior authorization before the patient has completed a full metformin trial. The claim denies, the patient gets frustrated, and the provider switches to a different medication rather than waiting another 30 days to resubmit. Patience during the metformin trial period has a higher success rate than switching strategies.

How Medicare coverage differs from Medi-Cal

Patients often confuse Medi-Cal (California's Medicaid program) with Medicare. The coverage rules for Ozempic differ substantially.

Medicare Part D (prescription drug coverage):

Medicare Part D plans are private insurance plans that contract with Medicare. Each plan maintains its own formulary. Most Part D plans cover Ozempic for diabetes with prior authorization, but the criteria and tier placement vary by plan.

Like Medicaid, Medicare Part D has a statutory exclusion for weight-loss drugs under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Ozempic prescribed for weight loss is not covered. Wegovy (the higher-dose semaglutide formulation approved specifically for weight loss) is not covered under any Part D plan.

Medi-Cal vs Medicare Part D comparison:

Feature	Medi-Cal	Medicare Part D
Ozempic for diabetes	Covered with PA	Covered with PA (plan-dependent)
Ozempic for weight loss	Excluded by federal statute	Excluded by federal statute
Wegovy	Not covered	Not covered
Typical copay (diabetes use)	$0 to $3	$35 to $150 (tier-dependent)
Prior authorization required	Yes, all plans	Yes, most plans

Dual-eligible patients (Medi-Cal + Medicare):

Patients who qualify for both Medi-Cal and Medicare (typically seniors or disabled individuals) receive prescription drug coverage through Medicare Part D, not Medi-Cal. The Medi-Cal program pays the Part D premiums and cost-sharing, but the coverage decisions follow Medicare Part D rules, not Medi-Cal rules.

For dual-eligible patients, the prior authorization criteria are often more lenient under Part D than under Medi-Cal managed care plans. A patient denied Ozempic under LA Care Medi-Cal might get approved under a Medicare Part D plan with Medi-Cal paying the copay.

The 2027 prediction: will California expand coverage?

The political and fiscal pressure to expand Medi-Cal coverage for GLP-1 medications is building, but the path to expansion is unclear.

Three scenarios for 2027:

Scenario 1: Federal statute change (low probability, high impact).

If Congress passes the Treat and Reduce Obesity Act or similar legislation removing the Medicaid weight-loss drug exclusion, California would be required to cover GLP-1s for obesity as a mandatory benefit. This would make Wegovy and Ozempic (when prescribed for weight loss) covered benefits with federal matching dollars.

Probability: 15%. The bill has bipartisan support but faces opposition from budget hawks concerned about the $30 billion to $50 billion annual cost to Medicaid nationwide.

Scenario 2: California state-funded optional benefit (moderate probability, moderate impact).

California could create a state-funded weight-loss medication benefit for Medi-Cal patients with BMI ≥ 35 plus comorbidities, similar to the failed AB 2085 proposal. This would require 100% state funding (no federal match) and would likely include strict prior authorization criteria to control costs.

Probability: 35%. Governor Newsom has expressed support for expanding obesity treatment access, but the $2.8 billion price tag is a barrier. A more likely version would cover only patients with BMI ≥ 40 or BMI ≥ 35 with diabetes, reducing the cost to $800 million to $1.2 billion annually.

Scenario 3: Status quo with incremental changes (high probability, low impact).

California maintains the current coverage framework (diabetes yes, weight loss no) but negotiates supplemental rebates with Novo Nordisk and Eli Lilly to reduce state costs for diabetes coverage. Prior authorization criteria remain in place but approval thresholds are lowered slightly (A1C ≥ 7.0% becomes standard across all plans).

Probability: 50%. This is the path of least resistance and requires no legislative action.

Our prediction: Scenario 3 is most likely for 2027, with Scenario 2 possible by 2028 if GLP-1 pricing drops below $400 per month retail. The federal statute change (Scenario 1) is unlikely before 2029 at earliest.

The wildcard is compounded semaglutide availability. If the FDA removes semaglutide from the drug shortage list (possible in late 2026 or 2027), compounding pharmacies would no longer be able to legally prepare compounded versions under Section 503A. This would eliminate the accessible cash-pay alternative, increasing political pressure for Medi-Cal coverage expansion.

FAQ

Does Medi-Cal cover Ozempic?

Medi-Cal covers Ozempic for type 2 diabetes with prior authorization but excludes coverage for weight loss under federal Medicaid statute. Approval requires documented A1C above 7.0% to 8.0% (plan-dependent) and a trial of metformin for at least 90 days.

Does Medi-Cal cover Ozempic for weight loss?

No. Federal Medicaid statute 42 U.S.C. § 1396r-8(d)(2) prohibits coverage of drugs used for weight loss. This exclusion applies regardless of BMI, comorbidities, or medical necessity. Medi-Cal cannot override this federal law.

Does Medi-Cal cover Wegovy?

No. Wegovy is semaglutide approved specifically for weight loss. It falls under the same federal statutory exclusion as Ozempic when prescribed for weight loss. Medi-Cal does not cover Wegovy under any circumstances.

What is the prior authorization process for Ozempic on Medi-Cal?

Your provider submits a prior authorization request to your managed care plan with documentation including A1C lab result, metformin trial records, and diabetes diagnosis code. The plan reviews and approves or denies within 3 to 10 business days depending on the plan. If denied, you can appeal.

How much does Ozempic cost without insurance in California?

The retail cash price for Ozempic is $968.52 per month for the 0.5 mg or 1 mg pen and $1,023.18 for the 2 mg pen as of April 2026. Pharmacy discount cards reduce this to $850 to $920 per month. Compounded semaglutide costs $199 to $399 per month.

Can I use a manufacturer coupon for Ozempic if I have Medi-Cal?

No. The Novo Nordisk Ozempic Savings Card explicitly excludes Medicaid and Medicare beneficiaries under federal anti-kickback statute. Medi-Cal patients cannot use manufacturer coupons or savings programs.

What A1C level do I need for Medi-Cal to cover Ozempic?

It depends on your managed care plan. Health Net and Kaiser require A1C ≥ 7.0%. Blue Shield Promise and Anthem require ≥ 7.5%. LA Care requires ≥ 8.0%. Check your plan's prior authorization criteria or ask your provider.

Does Medi-Cal cover compounded semaglutide?

No. Compounded medications are not covered under Medi-Cal. Compounded semaglutide is a cash-pay medication. The advantage is that it costs $199 to $399 per month vs $968.52 for brand-name Ozempic, and there is no prior authorization or formulary restriction.

What happens if Medi-Cal denies my Ozempic prior authorization?

You can appeal. The standard appeal process involves your provider submitting additional clinical documentation. If that denies, you can request independent medical review through the California Department of Managed Health Care. The approval rate on appeal is 34% for standard appeals and 58% for independent medical review.

Can my doctor prescribe Ozempic off-label for weight loss and bill Medi-Cal?

Your doctor can prescribe Ozempic off-label for weight loss, but Medi-Cal will not cover it. The claim will deny due to the federal statutory exclusion for weight-loss drugs. You would need to pay cash or use compounded semaglutide.

Does Medi-Cal cover Mounjaro or Zepbound?

Medi-Cal covers Mounjaro (tirzepatide) for type 2 diabetes with prior authorization, similar to Ozempic. Medi-Cal does not cover Zepbound (tirzepatide approved for weight loss) due to the same federal statutory exclusion that applies to Wegovy.

How long does Medi-Cal prior authorization take for Ozempic?

Turnaround time varies by managed care plan. Kaiser processes most prior authorizations in 2 to 4 business days. LA Care takes 7 to 10 business days. Expedited prior authorization (24 to 72 hours) is available if your provider documents urgent medical need.

Can I switch from Medi-Cal to private insurance to get Ozempic covered for weight loss?

If you qualify for private insurance (through an employer or Covered California), some private plans do cover GLP-1 medications for weight loss. However, you must actually qualify for and enroll in private coverage. You cannot simply opt out of Medi-Cal to access different drug coverage.

What is the difference between Ozempic and compounded semaglutide?

Ozempic is the FDA-approved brand-name product manufactured by Novo Nordisk. Compounded semaglutide is the same active ingredient prepared by a state-licensed compounding pharmacy. Compounded semaglutide is not FDA-approved, costs 70% to 80% less, and is available for cash-pay patients when Ozempic is not covered by insurance.

Does Medi-Cal cover diabetes medications other than Ozempic?

Yes. Medi-Cal covers metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, and insulin with varying levels of prior authorization requirements. Metformin is typically first-line and requires no prior authorization. Most other diabetes medications require prior authorization showing inadequate response to metformin.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
4. Cubanski J et al. Coverage of Anti-Obesity Medications Under Medicaid. Kaiser Family Foundation Issue Brief. 2024.
5. California Department of Health Care Services. Medi-Cal Rx Prior Authorization Denial Analysis Q4 2025. 2025.
6. California Department of Managed Health Care. Independent Medical Review Annual Report. 2025.
7. California Health Care Foundation. Medi-Cal Beneficiary Demographics and Income Data. 2025.
8. Omnibus Budget Reconciliation Act of 1990, 42 U.S.C. § 1396r-8(d)(2)(A). 1990.
9. House Report 101-881, Omnibus Budget Reconciliation Act of 1990 Legislative History. 1990.
10. Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Public Law 108-173. 2003.
11. Federal Food, Drug, and Cosmetic Act Section 503A, Pharmacy Compounding. 2013.
12. California Business and Professions Code Section 4052, Compounding Pharmacy Regulations. 2023.
13. FDA Drug Shortage Database, Semaglutide Injection. Updated April 2026.
14. American College of Gastroenterology. Clinical Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective manufacturers (Novo Nordisk and Eli Lilly and Company). GoodRx, SingleCare, and RxSaver are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.